ALKERMES | ALKS - Net Income

Stock Price
34.32
Daily Change
-0.64 -1.83%
Monthly
22.57%
Yearly
9.65%
Q1 Forecast
32.88

ALKERMES reported $82.76M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 938M 348M Jun/2025
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
ALKERMES USD 82.76M 4.34M Sep/2025
Amgen USD 3.22B 1.78B Sep/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Bristol-Myers Squibb USD 2.2B 891M Sep/2025
Eli Lilly USD 5.58B 78M Sep/2025
Gilead Sciences USD 3.05B 1.09B Sep/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
J&J USD 5.12B 36M Dec/2025
Malin Corporation EUR -1.1M 2.2M Dec/2023
Merck USD 5.78B 1.36B Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Otsuka Holdings JPY 124.13B 35.6B Sep/2025
Pfizer USD 3.54B 631M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025